Abbott Laboratories stock: BTIG cuts target to USD 125.00

Published on 10/23/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

USD 0.63 dividend was declared September 17, 2026. Abbott Laboratories stock costs EUR 91.41 on October 23, 2026, up 0.76 percent on EUR 90.72 Xetra close.

Analyst target and dividend

BTIG cut its Abbott target from USD 134.00 to USD 125.00 on October 22, 2026.
Abbott declared a USD 0.63 quarterly dividend on September 17, 2026.
Abbott Laboratories stock costs EUR 91.41 at Lang & Schwarz on October 23, 2026 at 4:11 p.m. CEST, 0.76 percent above the Xetra close of October 22, 2026 at EUR 90.72.
The stock has a price-to-earnings ratio of 37.66 and a market capitalization of USD 176.4 billion as of October 23, 2026.

SW-Reportage Blutlabor Mikroskop Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 schwarzweiße Reportage klinisches Blutbild-Labor Laborantin am Mikroskop dramatische Hochkontrast-Fotografie, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) received a BTIG target cut to USD 125.00 from USD 134.00 on October 22, 2026, as reported by Markets Insider. The new target stands 22.59 percent above the NYSE quote of USD 101.96 at 10:27 a.m. ET on October 23, 2026. Abbott Laboratories stock was trading at EUR 91.41 at Lang & Schwarz on October 23, 2026 at 4:11 p.m. CEST, up 0.76 percent versus the Xetra close of October 22, 2026 at EUR 90.72.

BTIG lowers its target by 6.72 percent

BTIG reduced its USD target by USD 9.00, a 6.72 percent cut from USD 134.00 to USD 125.00. The new level still sits above Abbott's same-day NYSE price, creating a clear gap between the research target and the listed share price.

The target change came one day after Abbott released its third-quarter results. That release is background here rather than the central market point: the company reported third-quarter sales of USD 13.013 billion for the period ended September 30, 2026, while adjusted diluted earnings per share reached USD 1.42, according to Abbott.

Stock range and valuation

Abbott's NYSE quote was USD 101.96 at 10:27 a.m. ET on October 23, 2026, within a 52-week range of USD 81.97 to USD 132.03. The market capitalization was USD 176.4 billion, and the price-to-earnings ratio was 37.66 at the same market snapshot.

The current euro quotation is 30.76 percent below the 52-week high when measured against the USD range only in its original currency, so the two currencies should not be combined. The euro move instead uses the Xetra close: EUR 91.41 was EUR 0.69 above EUR 90.72, equal to 0.76 percent.

Dividend payment comes next

Abbott declared a quarterly dividend of USD 0.63 per share on September 17, 2026. The payment is scheduled for November 16, 2026, to shareholders registered on October 15, 2026, according to Abbott. This gives the stock a trailing dividend yield of 2.00 percent as of October 23, 2026.

For investors, the key contrast is between the revised USD 125.00 target and the USD 101.96 NYSE quote. The euro quotation remains only a modest 0.76 percent above its Xetra comparison level.

Analyst target and market position

BTIG's revised target, the 52-week range and the dividend date provide three separate reference points for Abbott Laboratories stock. The company operates across diagnostics, medical devices, nutrition and established pharmaceuticals, with 115,000 full-time employees listed in company profile data.

Abbott Laboratories stock was trading at EUR 91.41 at Lang & Schwarz on October 23, 2026 at 4:11 p.m. CEST, up 0.76 percent versus the Xetra close of October 22, 2026 at EUR 90.72. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.